A5069953991- Hemophilia Treatment and Research
- Hemoglobinopathies and Related Disorders
- Blood Coagulation and Thrombosis Mechanisms
- Platelet Disorders and Treatments
- Iron Metabolism and Disorders
- Mosquito-borne diseases and control
- Blood groups and transfusion
- Viral Infections and Vectors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Malaria Research and Control
- Blood donation and transfusion practices
- Hemostasis and retained surgical items
- Venous Thromboembolism Diagnosis and Management
- Chronic Myeloid Leukemia Treatments
- Cancer-related gene regulation
- Erythrocyte Function and Pathophysiology
- Prenatal Screening and Diagnostics
- Viral Infections and Outbreaks Research
- Neonatal Health and Biochemistry
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood disorders and treatments
- Childhood Cancer Survivors' Quality of Life
Ramathibodi Hospital
2016-2025
Mahidol University
2016-2025
Pediatrics and Genetics
2006-2024
Humanitas University
2020
Istituti di Ricovero e Cura a Carattere Scientifico
2020
National Specialized Hospital for Active Treatment of Hematologic Diseases
2020
Queen Mary University of London
2020
Association of Directors of Environment, Economy, Planning and Transport
2010
GTx (United States)
2003-2010
The Royal Free Hospital
2008
Emicizumab is a subcutaneously administered humanized, bispecific, monoclonal antibody approved for prophylaxis in people with hemophilia A.
Thalassemia/hemoglobinopathy is a hereditary disease that causes chronic anemia and increased erythropoiesis. Consequently, an expansion of bone marrow spaces may contribute to osteopenia/osteoporosis. However, the pathogenesis changes not yet known. We, therefore, carried out study on histomorphometry biochemical hormonal profiles in children adolescents with suboptimally treated β-thalassemia hope gaining some new insight into cellular structural alterations thalassemic bone. Seventeen...
Abstract β‐Thalassemia intermediate patients show a remarkable clinical heterogeneity. We examined the phenotypic diversity of 950 β‐thalassemia/Hb E in an attempt to construct system for classifying disease severity. A novel scoring based on six independent parameters, hemoglobin level, age at presentation, receiving first blood transfusion, requirement spleen size, and growth development, was able separate into three distinctive severity categories: mild, moderate, severe courses. This...
The leakage of plasma during febrile episodes in dengue-infected patients is a severe condition leading to dengue shock syndrome. Alteration cytokines/chemokines suspected be major cause endothelial cell damage these patients. study was designed demonstrate the alteration cytokines and chemokines episodes.The blood samples from 164 with fever, hemorrhagic fever other illnesses were collected daily day hospitalization until discharge also convalescent stage. levels determined using sandwich...
Because of the very short half-life factor VII, prophylaxis in VII deficiency is considered a difficult endeavor. The clinical efficacy and safety prophylactic regimens, indications for their use, were evaluated VII-deficient patients Seven Treatment Evaluation Registry. Prophylaxis data (38 courses) analyzed from 34 with severe (10 years. No thrombosis or new inhibitors occurred. In conclusion, subset needed because bleeding. Recombinant activated schedules based on “frequent”...
Patients with severe thalassemia commonly have a survival that is significantly shorter than of the general population. Allogeneic hematopoietic stem cell transplantation (allo-SCT) only established treatment potentially curative, but it limited by availability donors and medical condition patient. To expand donor pool to include haploidentical related donors, we introduced program consisting pharmacologic pretransplant immune suppression phase (PTIS) 2 courses dexamethasone fludarabine,...
Background: To evaluate the use of dengue nonstructural protein 1 (NS1) antigen for early diagnosis during febrile stage in patients with infection. Methods: A total 445 sera obtained from 165 [dengue fever (DF): 42, hemorrhagic (DHF) grade I: 50, II: 63, III and IV: 10] 8 other illnesses 5–15 years age, were assayed NS1 antigen, dengue-specific Ig M G antibodies. Results: The positive rates among either DF or DHF was 100% (7 7) on day 2, 92.3% (12 13) 3, 76.9% (40 52) 4, 56.5% (61 108) 5...
Analysis of outcomes patients enrolled in the World Bleeding Disorders Registry (WBDR). 87 Hemophilia Treatment Centers around world participating WBDR. Data on 10,276 people with hemophilia demonstrate wide discrepancies care globally. Care provided low-income countries lags behind high-income by up to 40 years.
Accessibility to iron chelators including deferoxamine and deferasirox remains obscured in many developing countries. To provide an alternative, the government pharmaceutical organization of Thailand (GPO) manufactured deferiprone which has similar bioequivalent standard product. Seventy-three pediatric patients with severe β thalassemias, age range 3.2-19 years, were recruited a 1-year multicenter prospective, single arm, open label, dose escalating Phase III study determine its clinical...
Improving outcomes among class 3 thalassemia patients receiving allogeneic hematopoietic stem cell transplantations (HSCT) remains a challenge. Before HSCT, who were ≥ 7 years old and had liver size 5 cm constitute what the Center for International Blood Marrow Transplant Research defined as very high–risk subset of conventional high-risk group (here referred to HR). We performed HSCT in 98 with related unrelated donor cells. Seventy-six age < 10 received more myeloablative conditioning...
A paucity of data exists on the incidence, diagnosis and treatment bleeding in women with inherited factor VII (FVII) deficiency.Here we report results a comprehensive analysis from two international registries patients FVII deficiency, depicting clinical picture this disorder describing any gender-related differences.A fully compatible, deficiency (International Registry Factor IRF7; Seven Treatment Evaluation Registry, STER) was performed.In our cohort (N = 449; 215 male, 234 female),...
Recombinant activated factor VII (rFVIIa) was given to three children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Cases I II (girls aged 3 years 6 years, respectively) were diagnosed Dengue hemorrhagic fever prolonged shock. Case III, a boy 9 months, underwent left lobe hepatectomy for hepatoblastoma, during which 60% of his removed. This case complicated by myoglobinuria, renal impairment early All patients exhibited active bleeding. received...
A 14-year-old Thai boy presented because of a history headache, mandibular swelling, and facial nerve palsy. microorganism identified as Pythium insidiosum was cultured from the abscesses. Despite treatment with amphotericin B, iodides, ketoconazole, surgery, infection progressed. Magnetic resonance imaging (MRI) magnetic angiography (MRA) neck revealed an aneurysm in external carotid artery. The removed. MRA performed later showed stenosis internal Immunotherapy recommended last resort. One...
Thalassaemia/haemoglobinopathy is a hereditary disease causing increased erythropoiesis and expansion of the bone marrow cavity. As consequence, there reduction in trabecular tissue resulting osteopenia/osteoporosis. The present study was performed to assess mineral density (BMD) children adolescents with beta-thalassaemia determine biochemical hormonal changes that may affect BMD.Forty-eight were divided into two groups, transfusion-dependent (TD) (n = 16) transfusion-independent (TI) 32)....
Objectives We evaluated the efficacy and safety of recombinant activated factor VII (rFVIIa) in children aged < 18 years old with grade II or III Dengue hemorrhagic fever (DHF) who required blood component therapy for controlling bleeding episodes. Study design Patients were randomized to rFVIIa group placebo a ratio 2: 1. (100 μg/kg body weight) was given by intravenous bolus injection. When not effectively controlled, second dose μg/kg) 30 min after first dose. Results Nine 16 patients...
Background: Children with dengue hemorrhagic fever (DHF) are at risk to develop shock syndrome (DSS) for which neither marker has been demonstrated. Objective: The study was designed investigate the markers of vascular endothelial cell injuries and dysfunction that might be used as early predictors subsequent manifestation DSS. Methods: blood samples from 111 patients fever, DHF other febrile illness (OFI) were collected daily day admission until discharge convalescent stage. sample...
Recently published reports indicate that the outcome of unrelated donor transplantations in patients with leukemia is currently comparable to transplantation from identical family donors. We investigated possibly favorable outcomes related and children severe thalassemia. reviewed 49 consecutive thalassemia who underwent allogeneic stem cell related-donor (n=28) unrelated-donor (n=21) cells between September 1992 May 2005 at Faculty Medicine, Ramathibodi Hospital, Mahidol University...